Patient characteristics
| No. . | Age, y . | Sex . | Histology . | Stage . | No. of prior chemotherapies . | Time to last therapy preceding BSM, mo . | No. of relapses . | Dose, mg/m2/d . | No. of courses . | Involvement . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 26 | M | MC | 4B | 6 | 2 | 3 | 1 | 2 | Mediastinal, axillary, abdominal LN, hepatic infiltration | PD |
| 2 | 22 | F | MC | 4B | 3 | 7 | 2 | 2.5 | 2 | Supraclavicular and infraclavicular, mediastinal LN, pulmonary infiltration | PD |
| 3 | 42 | M | NS | 3A | 4 | 3 | 4 | 5 | 2 | Mediastinal and abdominal LN | PR, 5 mo |
| 4 | 40 | M | NS | 4B | 4 | 7 | 7 | 10 | 4 | Thoracic vertebrae 5-8 | PR for 4 wk, then chemotherapy for consolidation |
| 5 | 40 | M | MC | 3B | 3 | 18 | 1 | 20 | 2 | Cervical, axillary, abdominal, inguinal LN, splenic infiltration | SD |
| 6 | 35 | M | NS | 4B | 4 | 7 | 4 | 20 | 3 | Mediastinal LN, pulmonary plus thoracic wall infiltration | SD |
| 7 | 22 | F | NS | 4A | 2 | 2 | 1 | 20 | 2 | Mediastinal LN, pulmonary and hepatic infiltration | PR for 4 wk, then MR (response of hepatic lesion, pulmonary PD) |
| 8 | 53 | M | NS | 3A | 3 | 5 | 2 | 20 | 2 | Supraclavicular, axillary, mediastinal, abdominal, inguinal LN | SD |
| 9 | 35 | M | NS | 4A | 4 | 2 | 2 | 20 | 2 | Pulmonary infiltration | CR, 3 mo |
| 10 | 33 | M | NS | 4B | 4 | 6 | 3 | 20 | 2 | Mediastinal, axillary, abdominal LN, vertebral | SD |
| No. . | Age, y . | Sex . | Histology . | Stage . | No. of prior chemotherapies . | Time to last therapy preceding BSM, mo . | No. of relapses . | Dose, mg/m2/d . | No. of courses . | Involvement . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 26 | M | MC | 4B | 6 | 2 | 3 | 1 | 2 | Mediastinal, axillary, abdominal LN, hepatic infiltration | PD |
| 2 | 22 | F | MC | 4B | 3 | 7 | 2 | 2.5 | 2 | Supraclavicular and infraclavicular, mediastinal LN, pulmonary infiltration | PD |
| 3 | 42 | M | NS | 3A | 4 | 3 | 4 | 5 | 2 | Mediastinal and abdominal LN | PR, 5 mo |
| 4 | 40 | M | NS | 4B | 4 | 7 | 7 | 10 | 4 | Thoracic vertebrae 5-8 | PR for 4 wk, then chemotherapy for consolidation |
| 5 | 40 | M | MC | 3B | 3 | 18 | 1 | 20 | 2 | Cervical, axillary, abdominal, inguinal LN, splenic infiltration | SD |
| 6 | 35 | M | NS | 4B | 4 | 7 | 4 | 20 | 3 | Mediastinal LN, pulmonary plus thoracic wall infiltration | SD |
| 7 | 22 | F | NS | 4A | 2 | 2 | 1 | 20 | 2 | Mediastinal LN, pulmonary and hepatic infiltration | PR for 4 wk, then MR (response of hepatic lesion, pulmonary PD) |
| 8 | 53 | M | NS | 3A | 3 | 5 | 2 | 20 | 2 | Supraclavicular, axillary, mediastinal, abdominal, inguinal LN | SD |
| 9 | 35 | M | NS | 4A | 4 | 2 | 2 | 20 | 2 | Pulmonary infiltration | CR, 3 mo |
| 10 | 33 | M | NS | 4B | 4 | 6 | 3 | 20 | 2 | Mediastinal, axillary, abdominal LN, vertebral | SD |
M indicates male; F, female; MC, mixed cellularity; NS, nodular sclerosis; LN, lymph node; PD, progressive disease; SD, stable disease; PR, partial remission; and CR, complete remission.